Vistagen (NASDAQ:VTGN) presented exploratory clinical data for its investigational fasedienol nasal spray at Psych Congress 2026 in New Orleans on September 24, reporting findings from subgroup ...

The identification of subgroups of patients from randomized clinical trials that are of specific interest for guiding clinical decisions can be an attractive idea; however, since such trials are ...

You can find over one million groups to join on LinkedIn, the social media network for professionals. Topics vary from discussions about how to think creatively to learning something new such as ...

We conducted subanalyses of the combined results of the Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients (MOTIVATE) 1 and MOTIVATE 2 studies to better ...

HONG KONG, June 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") presented the subgroup analysis data from the Phase III COMPASSION-16 trial, evaluating cadonilimab, a ...

The values of the subgroup-variable, which is specified in the chart statement, indicate how the observations in the input data set (a DATA=, HISTORY=, or TABLE= data set) are arranged into rational ...

We evaluated the efficacy of raltegravir and the development of viral resistance in two identical trials involving patients who were infected with human immunodeficiency virus type 1 (HIV-1) with ...

Alternating neoadjuvant gemcitabine-nab-paclitaxel (GnP) and nal-irinotecan, 5-fluorouracil and folinic acid (nal-IRI) regimens in resectable (R) and borderline resectable (BR) pancreatic cancer (PC): ...

Of 882 participants enrolled, 128 had PD-L1 CPS < 1 and 373 had CPS 1-19. For pembrolizumab versus cetuximab-chemotherapy, the median overall survival was 7.9 versus 11.3 months in the PD-L1 CPS < 1 ...